Curated News
By: NewsRamp Editorial Staff
May 21, 2026
Optimi Health Prices $15M Offering for Nasdaq Uplisting
TLDR
- Optimi Health's Nasdaq uplisting and $15M raise positions it to scale psychedelic drug production for market advantage.
- Optimi Health prices 2.4M shares at US$6.25, consolidates shares 1-for-30, and expects Nasdaq trading May 20, 2026.
- Optimi Health's psychedelic drugs aim to improve mental health therapies, offering new hope for patients worldwide.
- Optimi Health supplies MDMA and psilocybin to Australia's Authorized Prescriber Scheme and Canada's Special Access Program.
Impact - Why it Matters
This news is significant because it signals a major step forward for the psychedelic medicine industry, as Optimi Health's uplisting to Nasdaq and capital raise will enable it to expand production of GMP-grade psychedelic drug products for mental health therapies. With increasing global interest in psychedelic-assisted therapies for conditions like PTSD and depression, Optimi's ability to scale and enter the US market could accelerate patient access to these treatments. For investors, the Nasdaq listing enhances liquidity and visibility, while the company's Health Canada license and international prescriptions demonstrate regulatory traction. This development may also encourage further investment and innovation in the psychedelic pharmaceutical sector.
Summary
Optimi Health Corp., a commercial-stage pharmaceutical company specializing in psychedelic drug products, has announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market. The offering consists of 2.4 million common shares at US$6.25 per share, with expected gross proceeds of approximately US$15 million. The company has also granted the underwriter, Joseph Gunnar & Co. LLC, an option to purchase up to an additional 360,000 shares. Trading on Nasdaq is expected to begin on May 20, 2026, under the ticker symbol OPTH. This strategic move marks a significant milestone for Optimi Health as it transitions from the Canadian Securities Exchange (CSE) to the prestigious Nasdaq, enhancing its visibility and access to capital markets.
Optimi Health intends to use the net proceeds from the offering to scale production and distribution of its psychedelic drug products, support market expansion including into the United States, and fund sales growth, working capital, and operating expenses. The company also confirmed the effectiveness of its previously announced 1-for-30 share consolidation, resulting in approximately 3.2 million common shares outstanding prior to the offering. Optimi Health is a Health Canada-licensed pharmaceutical manufacturer that produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
This news was disseminated through InvestorWire, a specialized communications platform that offers advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. The full press release can be accessed at https://ibn.fm/iwNJ5. For more information about Optimi Health, visit https://www.optimi.net/.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Optimi Health Prices $15M Offering for Nasdaq Uplisting
